Annabel Samimy
Stock Analyst at Stifel
(3.42)
# 923
Out of 4,947 analysts
54
Total ratings
43.75%
Success rate
27.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Initiates: Buy | $45 | $46.10 | -2.39% | 1 | Mar 26, 2025 | |
| GPCR Structure Therapeutics | Initiates: Buy | $50 | $18.53 | +169.83% | 1 | Jan 8, 2025 | |
| ALT Altimmune | Initiates: Buy | $18 | $3.68 | +389.13% | 1 | Jan 8, 2025 | |
| IVA Inventiva | Maintains: Buy | $20 → $17 | $4.22 | +302.84% | 4 | Nov 22, 2024 | |
| MBX MBX Biosciences | Initiates: Buy | $40 | $13.21 | +202.80% | 1 | Oct 8, 2024 | |
| KMDA Kamada | Initiates: Buy | $18 | $7.30 | +146.58% | 1 | Jul 3, 2024 | |
| PHAT Phathom Pharmaceuticals | Initiates: Buy | $24 | $10.47 | +129.23% | 1 | May 3, 2024 | |
| RGNX REGENXBIO | Maintains: Buy | $40 | $9.07 | +341.01% | 2 | Apr 12, 2024 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $80 | $40.24 | +98.81% | 6 | Mar 15, 2024 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $225 → $230 | $116.67 | +97.14% | 8 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 → $25 | $6.40 | +290.63% | 1 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $17.80 | +96.63% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $65 | $27.62 | +135.34% | 3 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $700 → $275 | $9.48 | +2,800.84% | 4 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $14.13 | +218.47% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 | $0.45 | +1,682.13% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $0.56 | +4,210.34% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $700 → $750 | $1.14 | +65,689.47% | 3 | Apr 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $25 → $24 | $42.17 | -43.09% | 7 | Apr 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $15 → $21 | $1.90 | +1,005.26% | 6 | Sep 18, 2019 |
Palvella Therapeutics
Mar 26, 2025
Initiates: Buy
Price Target: $45
Current: $46.10
Upside: -2.39%
Structure Therapeutics
Jan 8, 2025
Initiates: Buy
Price Target: $50
Current: $18.53
Upside: +169.83%
Altimmune
Jan 8, 2025
Initiates: Buy
Price Target: $18
Current: $3.68
Upside: +389.13%
Inventiva
Nov 22, 2024
Maintains: Buy
Price Target: $20 → $17
Current: $4.22
Upside: +302.84%
MBX Biosciences
Oct 8, 2024
Initiates: Buy
Price Target: $40
Current: $13.21
Upside: +202.80%
Kamada
Jul 3, 2024
Initiates: Buy
Price Target: $18
Current: $7.30
Upside: +146.58%
Phathom Pharmaceuticals
May 3, 2024
Initiates: Buy
Price Target: $24
Current: $10.47
Upside: +129.23%
REGENXBIO
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $9.07
Upside: +341.01%
Viking Therapeutics
Mar 15, 2024
Reiterates: Buy
Price Target: $80
Current: $40.24
Upside: +98.81%
Jazz Pharmaceuticals
Mar 15, 2024
Maintains: Buy
Price Target: $225 → $230
Current: $116.67
Upside: +97.14%
Mar 8, 2024
Reiterates: Buy
Price Target: $23 → $25
Current: $6.40
Upside: +290.63%
Oct 5, 2023
Initiates: Buy
Price Target: $35
Current: $17.80
Upside: +96.63%
Aug 29, 2023
Maintains: Buy
Price Target: $60 → $65
Current: $27.62
Upside: +135.34%
Jun 26, 2023
Downgrades: Hold
Price Target: $700 → $275
Current: $9.48
Upside: +2,800.84%
Mar 7, 2023
Initiates: Buy
Price Target: $45
Current: $14.13
Upside: +218.47%
Nov 10, 2022
Upgrades: Buy
Price Target: $8
Current: $0.45
Upside: +1,682.13%
Aug 24, 2021
Initiates: Buy
Price Target: $24
Current: $0.56
Upside: +4,210.34%
Apr 16, 2020
Maintains: Buy
Price Target: $700 → $750
Current: $1.14
Upside: +65,689.47%
Apr 16, 2020
Maintains: Hold
Price Target: $25 → $24
Current: $42.17
Upside: -43.09%
Sep 18, 2019
Maintains: Hold
Price Target: $15 → $21
Current: $1.90
Upside: +1,005.26%